URMC / Research / Clinical Trials / Study Details

Phase 3 Alogliptin Pediatric Study

Research Question:
Does the drug alogliptin help children age 10-17 with type 2 diabetes?

Basic Study Information

Purpose:
This study will evaluate the efficacy and safety of alogliptin 25 mg once daily (QD) compared to placebo when administered as monotherapy, or when added onto a background of metformin alone, insulin alone, or a combination of metformin and insulin in pediatric participants 10 to 17 years of age with type 2 diabetes mellitus (T2DM).

Location: University of Rochester

Study Contact Information

Study Coordinator: Takeda Study Registration Call Center
Email: medicalinformation@tpna.com

Additional Study Details

Contact This Study

First Name *

This field is required

Middle Name

Last Name *

This field is required

Phone Number

I agree to be contacted by The University of Rochester Medical Center regarding participation in this study. *

You must agree to be contacted to continue.

Please call me during the day.

Please call me during the evening.

Message

Return to Search

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Wilmot Clinical Trials

Phase 3 Alogliptin Pediatric Study

Basic Study Information

Study Contact Information

Additional Study Details

Contact This Study

Trial Not Found